Free Newsletter
Are investors overreacting to Amylin news?
Bad news from the FDA can hurt pharma companies fast and after earlier news this week that Amylin's diabetes drug Byetta was associated with some serious cases of acute pancreatitis, the company's stock began to plummet. Shares were down 13 percent by Monday.
Eli Lilly, which co-markets the drug, isn't receiving equally harsh treatment from investors.
What is interesting is that the there were already 30 reports of pancreas related problems in October. The latest news added six more reports, two of which led to deaths and were quite serious, but was in light of patients with diabetes already being at increased risk of pancreas problems. Later, in an interview with the Diabetic Investor, the FDA said the news was actually about a "rare and uncommon event."
Finance experts say the stock will likely recover and that panic in the industry can provide a great opportunity for investors who want to buy low.
--catch the story at the Motley Fool
--read more at Forbes
--see the latest at Sign on San Diego
Related Articles:
FDA seeks tougher labeling for Byetta after deaths
Lilly diabetes med linked to pancreatitis
Byetta - Top 10 Drug Warnings and Recalls
FDA Updates Information for Healthcare Professionals for Byetta
Comments
Here's a tip for Marcea Bland Lloyd. Moore and Labriola represented GSK for years, including regarding Avandia, and they still have friends there. If GSK has gained a competitive advantage from this lawsuit, I'd look closely at whether these plaintiffs' lawyers are receiving inside tips and/or expert advice from old friends.
Post new comment
Paid Research Reports
- The Top 10 Biosimilar Players: Positioning, performance and SWOT analyses
- New Approaches to Pharma R&D: Evolving strategies to rejuvenate R&D efficiency
- Stakeholder Opinions: Vaccine antigen delivery technologies - Molecular systems to open new markets
- The Top 10 Contract Research Organizations
- Stakeholder Opinions: Vaccine administration technologies - Beyond needles
- Future Pharmaceutical Industry Trends: Long-term opportunities tempered by short-term challenges





Click here to get the FiercePharma email newsletter for FREE!
Comments (1) | Post a comment